NCT07253896

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab as Second-line Treatment in MSS Type Metastatic Colorectal Cancer Based on RAS Gene Status

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer

Detailed description

This study is a single arm, open label, single center clinical study aimed at evaluating the efficacy and safety of candenizumab combined with chemotherapy and targeted drugs (cetuximab or bevacizumab) in second-line treatment of MSS type advanced metastatic colorectal cancer.

Conditions

• Safety

Interventions

Type	Name	Description
DRUG	AK104 and cetuximab or bevacizumab and FOLFIRI	AK104 and cetuximab or bevacizumab and FOLFIRI as the second line

Timeline

• Start date: 2024-01-03
• Primary completion: 2026-01-03
• Completion: 2027-01-03
• First posted: 2025-11-28
• Last updated: 2025-11-28

Locations

2 sites across 1 country: China